Extended-release tofacitinib for refractory Behçet disease: A case report

RATIONALE: Although single-cytokine inhibitors can be considered in treating severe or refractory Behçet disease (BD), these biologic agents are associated with potential therapeutic failure due to the multi-cytokine pathogenesis involving Th1- and Th17-type cytokines with activated Janus kinase/sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chrong-Reen, Wong, Tak-Wah, Hsu, Sheng-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
6900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276400/
https://www.ncbi.nlm.nih.gov/pubmed/35475806
http://dx.doi.org/10.1097/MD.0000000000029189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276400/
https://www.ncbi.nlm.nih.gov/pubmed/35475806
http://dx.doi.org/10.1097/MD.0000000000029189

Ejemplares similares